Insmed Incorporated (NASDAQ:INSM) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET

Company Participants

Eleanor Barisser - Investor Relations

Will Lewis - Chair & Chief Executive Officer

Sara Bonstein - Chief Financial Officer

Conference Call Participants

Jeff Hung - Morgan Stanley

Andrea Tan - Goldman Sachs

Judah Frommer - Credit Suisse

Joori Park - SVB Securities

Stephen Willey - Stifel

Jennifer Kim - Cantor Fitzgerald

Operator

Good morning. My name is Dennis, and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed Second Quarter 2022 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator instructions]

I would now like to turn the conference over to Eleanor Barisser, Investor Relations. Please go ahead.

Eleanor Barisser

Thank you, Dennis. Good morning, and welcome to today's conference call to discuss our second quarter financial results for 2022 and to provide a business update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, which are available through the SEC's website at www.sec.gov or from our website for information concerning the risk factors that could affect the company. The information on today's call is not intended for promotional purposes and not sufficient for prescribing decisions.

Joining me on today's call are members of the Insmed Executive Management team, including Will Lewis, Chair and Chief Executive Officer and Sara Bonstein, Chief Financial Officer.

Let me now turn the call over to Will Lewis for prepared remarks. Upon completion of those remarks, we will open the call up for your questions.

Will Lewis

Thank you, Eleanor. Good morning, everyone. Insmed finished the second quarter of 2022 in a stronger position than ever before as we continue to execute effectively across the four pillars of our business. Our global commercial operations are advancing, evidenced by the tremendous second quarter sales of ARIKAYCE. The second quarter marked our highest active number of patients on therapy since launch.

Building on this success, we are advancing a robust pipeline that we expect will deliver transformative improvements to patients' lives and create significant shareholder value. On the clinical development side, our ability to attract patients into our clinical trials has been strong and all of our clinical programs are continuing to tract in line with our expectations.